Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Asthma Data Innovation Demonstration Project
Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management
Status: Enrolling
Updated:  12/23/2017
Jefferson County
mi
from
Louisville, KY
Asthma Data Innovation Demonstration Project
Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management
Status: Enrolling
Updated: 12/23/2017
Jefferson County
mi
from
Louisville, KY
Click here to add this to my saved trials
Electrical Stimulation for Hemiplegic Shoulder Pain
Electrical Stimulation for Hemiplegic Shoulder Pain
Status: Enrolling
Updated:  12/26/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Electrical Stimulation for Hemiplegic Shoulder Pain
Electrical Stimulation for Hemiplegic Shoulder Pain
Status: Enrolling
Updated: 12/26/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Status: Enrolling
Updated:  12/27/2017
Columbia University Medical Center
mi
from
New York, NY
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Status: Enrolling
Updated: 12/27/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Heart Rate Variability in Response to Metformin Challenge
Heart Rate Variability in Response to Metformin Challenge
Status: Enrolling
Updated:  12/30/2017
Woodinville Psychiatric Associates
mi
from
Woodinville, WA
Heart Rate Variability in Response to Metformin Challenge
Heart Rate Variability in Response to Metformin Challenge
Status: Enrolling
Updated: 12/30/2017
Woodinville Psychiatric Associates
mi
from
Woodinville, WA
Click here to add this to my saved trials
Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury
Imaging [18F]AV-1451 and [18F]AV-45 in Acute and Chronic Traumatic Brain Injury
Status: Enrolling
Updated:  1/2/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury
Imaging [18F]AV-1451 and [18F]AV-45 in Acute and Chronic Traumatic Brain Injury
Status: Enrolling
Updated: 1/2/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy
Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy (TIPN)
Status: Enrolling
Updated:  1/2/2018
Greenville Health System Cancer Institute Center for Integrative Oncology and Survivorship
mi
from
Greenville, SC
Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy
Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy (TIPN)
Status: Enrolling
Updated: 1/2/2018
Greenville Health System Cancer Institute Center for Integrative Oncology and Survivorship
mi
from
Greenville, SC
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Birmingham, AL
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Los Angeles, CA
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Kansas City, KA
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
New York, NY
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
Clinical Research Facility
mi
from
Palo Alto, CA
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated:  1/3/2018
mi
from
Lyon,
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Status: Enrolling
Updated: 1/3/2018
mi
from
Lyon,
Click here to add this to my saved trials
Asymmetrical Gait Training After Pediatric Stroke
Motor Outcomes and Neural Correlates of Asymmetrical Gait Training in Children With Acquired Hemiplegia
Status: Enrolling
Updated:  1/3/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Asymmetrical Gait Training After Pediatric Stroke
Motor Outcomes and Neural Correlates of Asymmetrical Gait Training in Children With Acquired Hemiplegia
Status: Enrolling
Updated: 1/3/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)
A Proof-of-principle Clinical Study Investigating the Efficacy of a Dissolvable Strip in Providing Rapid Relief From Dentinal Hypersensitivity.
Status: Enrolling
Updated:  1/3/2018
GSK Investigational Site
mi
from
Las Vegas, NV
To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)
A Proof-of-principle Clinical Study Investigating the Efficacy of a Dissolvable Strip in Providing Rapid Relief From Dentinal Hypersensitivity.
Status: Enrolling
Updated: 1/3/2018
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Toledo Health Science Campus
mi
from
Toledo, OH
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Toledo Health Science Campus
mi
from
Toledo, OH
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Medical University of South Carolina
mi
from
Charleston, SC
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
City of Hope National Medical Center
mi
from
Duarte, CA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
UCLA Medical School
mi
from
Los Angeles, CA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
UCLA Medical School
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Kentucky
mi
from
Lexington, KY
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Massachusetts General Hospital
mi
from
Boston, MA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Boston University School of Medicine
mi
from
Boston, MA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Boston University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Michigan
mi
from
Ann Arbor, MI
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Duke University
mi
from
Durham, NC
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Texas- Houston Medical School
mi
from
Houston, TX
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Texas- Houston Medical School
mi
from
Houston, TX
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
Fred Hutchinson Cancer Research Center (FHCRC)
mi
from
Seattle, WA
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
Fred Hutchinson Cancer Research Center (FHCRC)
mi
from
Seattle, WA
Click here to add this to my saved trials
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated:  1/4/2018
University of Calgary
mi
from
Calgary,
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)
Status: Enrolling
Updated: 1/4/2018
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Status: Enrolling
Updated:  1/5/2018
Johns Hopkins University
mi
from
Baltimore, MD
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Status: Enrolling
Updated: 1/5/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Harmonex Neuroscience Research
mi
from
Dothan, AL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Harmonex Neuroscience Research
mi
from
Dothan, AL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
ProScience Research Group
mi
from
Culver City, CA
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
ProScience Research Group
mi
from
Culver City, CA
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Sarkis Clinical Trials
mi
from
Gainesville, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Indago Research & Health Center, Inc.
mi
from
Hialeah, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Indago Research & Health Center, Inc.
mi
from
Hialeah, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Miami Research Associates
mi
from
South Miami, FL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
iResearch Atlanta LLC
mi
from
Decatur, GA
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
iResearch Atlanta LLC
mi
from
Decatur, GA
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Capstone Clinical Research
mi
from
Libertyville, IL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Baber Research Group
mi
from
Naperville, IL
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Baber Research Group
mi
from
Naperville, IL
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Pedia Research, LLC
mi
from
Newburgh, IN
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Pedia Research, LLC
mi
from
Newburgh, IN
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Psychiatric Associates
mi
from
Overland Park, KA
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Psychiatric Associates
mi
from
Overland Park, KA
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Pedia Research LLC
mi
from
Owensboro, KY
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Pedia Research LLC
mi
from
Owensboro, KY
Click here to add this to my saved trials
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/5/2018
Neurobehavioral Medicine Group, Clinical Trials Division
mi
from
Bloomfield Hills, MI
Dasotraline Pediatric Extension Study
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/5/2018
Neurobehavioral Medicine Group, Clinical Trials Division
mi
from
Bloomfield Hills, MI
Click here to add this to my saved trials